首页> 外文期刊>Journal of Medical Virology >Claudin-1 Gene Variants and Susceptibility to Hepatitis C Infection in HIV-1 Infected Intravenous Drug Users (an ANRS Case-Control Study)
【24h】

Claudin-1 Gene Variants and Susceptibility to Hepatitis C Infection in HIV-1 Infected Intravenous Drug Users (an ANRS Case-Control Study)

机译:Claudin-1基因变异和HIV-1感染的静脉吸毒者对丙型肝炎感染的易感性(ANRS病例对照研究)

获取原文
获取原文并翻译 | 示例
           

摘要

Hepatitis C virus (HCV) seroprevalence is highly diverse among human immunodeficiency virus-1 (HIV-1) infected patients, ranging between 10% of HIV-1 infected homo-bisexuel men, to >92% in patients infected with HIV-1 who acquired HIV-1 through intravenous drug use. Thus, being HCV-free while having acquired HIV-1 via intravenous drug use is a rare situation. Claudin-1 is a protein involved in intracellular tight-junctions and has been identified as a major cellular co-receptor for HCV infection. Our objective was to determine whether Claudin-1 gene (CLDN1) mutations might be involved in natural resistance to HCV infection. We conducted a case-control study. All recruited patients acquired HIV-1 infection via intravenous drug use route before 1995. The case study patients remained free from HCV infection (negative anti-HCV antibodies and HCV-RNA). The control study patients was co-infected with HCV (positive anti-HCV antibodies). Direct genomic sequencing of the CLDN1 gene coding region and adjacent intron/exons junctions was performed from peripheral blood mononuclear cells. A total of 138 Caucasian patients were enrolled. Twenty-two patients (cases) were free from HCV infection and 116 (controls) were co-infected with HCV. We found single nucleotide polymorphisms (SNPs) described previously with no significant differences in allele frequencies between cases and controls. In conclusion, despite being a major cellular co-receptor for HCV entry in vitro, we did not identify any specific substitution in CLDN1 gene coding region in our study patients highly exposed but resistant to HCV infection in vivo. Other cellular co-factors involved in HCV infection should be investigated in this highly-exposed intravenous drug users patients. J. Med. Virol. 87:619-624, 2015. (c) 2015 Wiley Periodicals, Inc.
机译:在感染人类免疫缺陷病毒1(HIV-1)的患者中,丙型肝炎病毒(HCV)的血清阳性率差异很大,介于感染HIV-1的同性双性恋男性中的10%,到感染HIV-1的患者中> 92%通过静脉吸毒获得HIV-1。因此,在通过静脉吸毒获得HIV-1的同时不含HCV是一种罕见的情况。 Claudin-1是一种参与细胞内紧密连接的蛋白质,已被确定为HCV感染的主要细胞共受体。我们的目标是确定Claudin-1基因(CLDN1)突变是否可能与HCV感染的自然抵抗力有关。我们进行了病例对照研究。所有入选患者均于1995年之前通过静脉吸毒途径获得HIV-1感染。本案例研究患者仍未感染HCV(抗HCV抗体阴性和HCV-RNA)。对照研究患者被HCV(抗-HCV阳性抗体)共感染。从外周血单核细胞进行CLDN1基因编码区和相邻的内含子/外显子连接的直接基因组测序。总共招募了138名白人患者。 22例患者(病例)未感染HCV,116例(对照组)被HCV合并感染。我们发现先前所述的单核苷酸多态性(SNP)在病例和对照之间的等位基因频率上没有显着差异。总之,尽管它是体外HCV进入的主要细胞共受体,但在我们高度暴露但对体内HCV感染具有抗性的研究患者中,我们并未在CLDN1基因编码区中发现任何特异性取代。在这种高度暴露的静脉吸毒者中,应调查涉及HCV感染的其他细胞辅助因子。 J. Med。病毒。 87:619-624,2015.(c)2015威利期刊公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号